Diabetes mellitus

Deutsche Apotheker Zeitung

Volumn 139, Issue 30, 1999, Pages 31-34

  Von Menzel, Ruth ^a   Kerner, W ^a   Bruns, W ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ASPART INSULIN; GLIBENCLAMIDE; GLITABON; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; MIGLITOL; NEW DRUG; PIOGLITAZONE; RECOMBINANT HUMAN INSULIN; REPAGLINIDE; ROSIGLITAZONE; SIBUTRAMINE; SILDENAFIL; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNCLASSIFIED DRUG;

DRUG MECHANISM; HUMAN; HYPERLIPOPROTEINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; WEIGHT REDUCTION;

EID: 0033614937     PISSN: 00119857     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Balfour, J. A., Faulds D. (1998) Repaglinide. Drugs &Acingl3: 173-180.
2. Berger, W., Caduff, F Pasquel, M. (1986). Die relative Häufigkeit der schweren SulfonylharnstoffHypoglykämie in den letzten 25 Jahren in der Schweiz. Schweiz Med Wochenschr. 116: 145-151.
3. Canovatchel, W. (1998). The safety of anti-obesity treatment with the novel lipase-inhibitor, orlistat (Xenical TM): An overview. Diabctologia 41: Suppl. 1,231 (Abstr.).
4. Cefalu, W. T., Gelfand, R. A., Kourides, I. A. (1998). A three-month, multicenter clinical trial of therapy with inhaled human insulin in type 2 diabetes mcllitus. Diabetologia41: Suppl. 1, 872 (Abstr.).
5. Damsbo, P., Perentesis, G., Müller, P. G. et al. (1997). Favorable tolerability profile of repaglinide in N1DDM after multiple ascending doses. J. Clin. Pharmacol 37: 875 (Abstr.).
6. Diederen, W., Kolb, W. (1997). Repaglinide, a new rapid and short-acting non-sulphonylurea insulin secretagogue inhibits ATP-sensitive potassium channels (IKATP) in isolated heart muscle cells. Diabetologia 40: Suppl. 1, 1274 (Abstr.).
7. Ferner, R. E., Neu, H. A. W. (1988). Sulphonylureas and hypoglycaemia. Br. Med. J. 296: 949-950.
8. Fuhlendorff, J., Rorsman, P., Koford, H. et al. (1998). Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47: 345-351.
9. Goldstein, I., Lue, T. F., Padma-Nathan, H. et al. (1998). Oral sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med. 338: 1397-1403.
10. Henrichs, H. R., Haak, T., Hecker, \V. (1998). (Be-)merkenswertes vom ADA-Kongreß '98. Diabetes und Stoffwechsel 7: 165-166.
11. Hollander, P. A., Elbein, S. C, Hirsch, I. B. et al. (1998). Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 21 : Nr. 8, 1288-1294.
12. Landgraf, R., Bilo, H. J. G. (1997). Repaglinide vs glibcnclamid: a 14-week efficacy and safety comparison. Diabetologia 40: Suppl. l, A321, 1262 (Abstr).
13. Lebovitz, H. E., Patel, J., Dole, J., Patwardhan, R. (1998). Rosiglitazone (BRL 49653) monotherapy has significant glucose-lowering effect in type 2 diabetic patients. Diabetologia 41 Suppl. 1: 922 (Abstr.).
14. Lindholm, A., McEwen, J., Riis, A. (1998). Significantly improved postprandial glycaemic control with the novel rapid-acting insulin aspart. Diabetologia 41: Suppl. 1, 185 (Abstr.).
15. McNeely, W., Benfield, P. (1998). Orlistat. Drugs 56: 241-249.
16. Moses, R., Slobodniuk, R., Boyages, S., et al. (1997). Additional treatment with repaglinide provides significant improvement in glycaemic control in NIDDM patients poorly controlled on metformin. Diabetologia40: Suppl. l, A322, 1266 (Abstr).
17. Pieber, T. R., Eugene-Jolchine, I., Derobert, E. (1998). Efficacy and safety of HOE 901 in patients with type 1 diabetes: A four-week randomised, NPH Insulin-controlled trial. Diabetologia 41: Suppl. 1, 187 (Abstr.).
18. Rende!!, M. S., Moreno, F. (1998). A double-blind, placebo-controlled, flexible dose-escalation study assessing the efficacy and safety of silderiafil (VIAGRA TM) in men with erectile dysfunction and diabetes. Diabetes 47: 0033 (Abstr.). '
19. Sinha, K., Weyer, C., Loftager, M., Hirschberger, S., Heise, T., Heinemann, L. (1998). Time-action profile of the soluble, fatty acid acylated long-acting insulin analogue NN304. Diabetologia 41: Suppl. 1, 188 (Abstr.).
20. Skyler, J. S., Gelfand, R. A., Kourides, I. A. ( 1998). A three-month, multicenter clinical trial of therapy with inhaled human insulin in type 1 diabetes mellitus. Diabetologia 41: Suppl. 1, 169 (Abstr.).
21. Standl, E., Willms, B. (1998). Ein Rückschlag für die Diabetologie. Diabetes und Stoffwechsel 7: l -2.
22. Stumvoll, M. (1998). Troglitazone. Diabetes und Stoffwechsel 7: 136-143.
23. Tonstad, S., Pometta, D., Erkelens, D. et al. (1994). The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur. J. Clin. Pharmacol. 46:405-410.
24. Vinambres, C., Villanueva-Penacarrillo, M. L., Valverde, I., Malaisse, W. J. (1996). Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets. Pharmacological Research 34, No. 1/2:83-85.
25. Willms, B. (1998). 58. Jahrestagung der Amerikanischen Diabetesgesellschaft. Diabetes und Stoffwechsel 7: 163-164.
26. Informationen der Firma BASF Pharma/Knoll (1998): Adipositas - Gefahr im Verborgenen.
27. Adipositas - Beratungsprogramm der Firma BASF Pharma/Knoll (1998): Reducto - Das AdipositasProgramm.
28. Fachinformation Miglitol (1998).